High-throughput screening of AAV vector capsid libraries reveals unexpected insights

High-throughput screening of AAV vector capsid libraries reveals unexpected insights

Coronavirus spreads even without symptoms and how Hangzhou province contained virus spread Among the most important findings was the following: it is not essential to use multiple rounds of selection, and this may in fact be counterproductive. Functional and efficient AAV variants were obtained after only one round of selection. Additionally, infection with a high multiplicity of infection (MOI) is preferable to infection with a low MOI, as the use of low MOIs results in more variation between screens and is not optimal at selecting the most desired capsids. Furthermore, competition can take place between AAVs with specific capsids in cells that. Have been infected with different AAVs. Other key findings are outlined in the article. This cutting-edge work by Dr. Kay and his Stanford colleagues is helping to make directed evolution of AAV capsids less of a 'black box'. His insights are likely to result in the discovery of important novel capsids that might otherwise be overlooked." Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA Source: Mary Ann Liebert, Inc. Journal reference: de Alencastro, G., et al. (2020) Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing. Human Gene Therapy . doi.org/10.1089/hum.2019.339 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More